Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Rheumatoid Arthritis Age: Adult Condition: Inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies |
Dose: by mouth – 2 mg Frequency: once daily Note: May be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs) |
|
Indication: Alopecia Areata Age: Adult Condition: Severe alopecia areata |
Dose: by mouth – 2 mg Frequency: once daily Note: Increase to 4 mg once daily if inadequate response |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: COVID-19 (Emergency Use Authorization) Age: less than 2 years |
Dose: Not authorized Note: Emergency use authorization issued by the FDA for treatment of suspected or laboratory confirmed coronavirus disease 2019 (COVID-19) in hospitalized patients who require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) |
|
Indication: COVID-19 (Emergency Use Authorization) Age: 2 to less than 9 years Condition: Hospitalized requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) |
Dose: Tablet – 2 mg Frequency: once daily Duration: 14 days or until hospital discharge, whichever comes first Note: by mouth (oral); optimal treatment duration unknown |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Rheumatoid arthritis Condition: Mild renal impairment (eGFR 60 to less than 90 mL/min/1.73 m2) |
Dose: Tablet – No dose adjustment required Note: eGFR 60 to less than 90 mL/min/1.73 m2 |
|
Indication: Rheumatoid arthritis Condition: Moderate renal impairment (eGFR 30 to less than 60 mL/min/1.73 m2) |
Dose: Tablet – 1 mg Frequency: once daily Note: eGFR 30 to less than 60 mL/min/1.73 m2 |
Administration
- Take with or without food
- Take once daily
Side Effect
- Upper respiratory tract infection (URTI) (16.3%)
- Nausea (2.7%)
- Increased LFTs (1-2%)
- Platelet elevations (1-2%)
- Herpes zoster infection (1%)
- Acne (Less than 1%)
- Herpes simplex infection (0.8%)
- Neutropenia (0.3%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Live vaccines
|
Avoid use
|
|
Strong OAT3 inhibitors
|
May increase baricitinib systemic exposure
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store below 30°C. Protect from light & moisture. Keep all medicines out of the reach of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.